TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ritu Baral’s rating is based on several factors that highlight GH Research’s potential for growth and development. The company is actively engaging with the FDA to address a remaining issue related to rat histology findings, which is crucial for lifting the clinical hold on their GH001 IND. GH Research is leveraging expert consultants and additional data to strengthen their case, indicating a proactive approach to regulatory challenges.
Furthermore, the company’s financial health appears robust, with a cash balance of $293.9 million, providing a runway into 2027. This financial stability, combined with the anticipated start of their Phase 3 TRD program in 2026, positions GH Research well for future advancements. These strategic efforts and financial positioning contribute to Ritu Baral’s Buy rating for GH Research’s stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.